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Background: In vertebrates, canonical Hedgehog (Hh) pathway activation 
requires Smoothened (SMO) translocation to the primary cilium (Pc), followed 
by a GLI-mediated transcriptional response. In addition, a similar gene 
regulation occurs in response to growth factors/cytokines, although 
independently of SMO signalling. The Hh pathway plays a critical role in liver 
fibrosis/regeneration, however, the mechanism of activation in chronic liver 
injury is poorly understood. This study aimed to characterise Hh pathway 
activation upon thioacetamide (TAA)-induced chronic liver injury in vivo by 
defining Hh-responsive cells, namely cells harbouring Pc and Pc-localised 
SMO. 
Methods: C57BL/6 mice (wild-type or Ptc1+/-) were TAA-treated. Liver injury 
and Hh ligand/pathway mRNA and protein expression were assessed in vivo. 
SMO/GLI manipulation and SMO-dependent/independent activation of GLI-
mediated transcriptional response in Pc-positive (Pc+) cells were studied in 
vitro. 
Results: In vivo, Hh activation was progressively induced following TAA. At 
the epithelial-mesenchymal interface, injured hepatocytes produced Hh 
ligands. Progenitors, myofibroblasts, leukocytes and hepatocytes were GLI2+. 
Pc+ cells increased following TAA, but only EpCAM+/GLI2+ progenitors were 
Pc+/SMO+. In vitro, SMO knockdown/hGLI3-R overexpression reduced 





with hGLI1 overexpression. HGF induced GLI transcriptional activity 
independently of Pc/SMO. Ptc1+/- mice exhibited increased progenitor, 
myofibroblast and fibrosis responses. 
Conclusions: In chronic liver injury, Pc+ progenitors receive Hh ligand signals 
and process it through Pc/SMO-dependent activation of GLI-mediated 
transcriptional response. Pc/SMO-independent GLI activation likely occurs in 
Pc-/GLI2+ cells. Increased fibrosis in Hh gain-of-function mice likely occurs by 
primary progenitor expansion/proliferation and secondary fibrotic 






Chronic liver diseases are characterised by persistent injury directed at 
hepatic epithelial cells, specifically biliary cells and hepatocytes. The resulting 
epithelial damage and hepatic inflammation drives a progressive intrahepatic 
fibrotic response[1]. This is in concert with an epithelial regenerative response 
that combines repopulation from mature hepatocytes and activation, 
proliferation and differentiation from liver progenitor cells (LPCs). The LPC 
response, or ductular reaction, has been well characterised in human and 
experimental chronic liver disease[2]. These heterogeneous cells, sharing 
combinations of progenitor, biliary and hepatocyte markers, are located at the 
epithelial-mesenchymal interface, with isolated cells in the adjacent lobule. 
Important pathogenic processes in the liver occur within anatomical 
microenvironments or niches. Hedgehog (Hh) signalling plays a critical role in 
mediating cell fate, growth and differentiation of epithelial stem/progenitor cell 
niches that reside within various adult tissues[3-6]. In the absence of Hh 
ligands, this family consisting of Sonic Hh (SHH), Indian Hh (IHH) and Desert 
Hh (DHH), the pathway is transcriptionally repressed. Binding of 
SHH/IHH/DHH to the receptor Patched1 (PTCH1) leads to the de-repression 
and subsequent activation of transmembrane protein Smoothened (SMO), 
which transduces the signal to downstream effectors. This results in 
stabilisation of the GLI-Kruppel (GLI) family of transcription factors into their 
full-length activator form (GLI-A), eliciting the Hh transcriptional response[7]. 
In recent years, two important observations have significantly changed our 





ligand signal into a GLI transcriptional response is dependent on translocation 
of SMO into the primary cilia (Pc), an immotile membrane-bound sensory 
organelle found on most vertebrate cells[8-10]. Secondly, growing evidence 
suggests the expression of GLI genes per se, and consequently the 
downstream GLI-mediated transcriptional response, can be modulated by 
cytokines and growth factors; and decoupled from the Hh/PTCH1/Pc/SMO-
cascade[11-15]. 
The Hh signalling pathway is classically recognised for its integral role in 
embryonic patterning during development, with aberrant activation of this 
pathway in adult tissues associated with malignancy. More recently, Hh 
pathway involvement has been studied in liver disease pathogenesis. A 
paradigm has emerged where Hh ligand production and SMO-dependent GLI 
signalling exists within multiple liver cell populations[16]. In particular, it has 
been proposed that Hh pathway activation is important in perpetuating an 
activated pro-fibrogenic phenotype[16, 17]. Studies have also reported the Hh 
pathway is involved in liver regeneration, and in the maintenance of 
intrahepatic stem/progenitor cells[16, 18]. A major limitation of these studies is 
that Hh signalling activation in vivo is only defined by GLI2 expression. As 
such, it has been impossible to define whether GLI regulation is SMO-
dependent or SMO-independent, in the proposed paradigm. 
In this paper, for the first time, we have used Pc detection to carefully identify 
Hh-responsive cells in chronic liver disease that co-express corresponding 
SMO and GLI proteins in vivo. We have defined the ligand-dependent, SMO-





Signalling Niche of Hedgehog’. High level GLI2 expression was also detected 
in several cell populations that lacked a Pc. Since Pc are crucially required for 
SMO-dependent Hh signalling[8], we hypothesise these cells elicit a SMO-
independent GLI-mediated response, potentially driven by cytokines/growth 
factors associated with chronic liver disease[1]. Our observations demonstrate 
GLI activation in chronic liver disease occurs, at least, by two mechanisms. 
Such observations are critically important given the potential for Hh pathway-
related therapeutics in liver disease treatment. 
MATERIALS AND METHODS 
Animal studies 
Housing/experiments at the Centenary Institute performed in accordance with 
protocols imposed by the Animal Ethics Committee, University of Sydney 
(K75/2-2010/3/5209, K75/1-2010/3/5210). To induce progressive liver injury, 
eight-week old C57BL/6 male mice were thioacetamide (TAA)-treated 
(300mg/L; MP Biomedicals, USA) in drinking water ad libitum for 4, 8, or 20 
weeks (wks) (n=3-10/group) prior to sacrifice. Non-treated control littermates 
were sacrificed at 20wks. Altered Hh pathway activation in vivo was studied 
using heterozygous Ptc1-lacZ reporter (Ptc1+/-) mice[19]. Eight-week wild-type 
(wt) or Ptc1+/- male mice were TAA-treated for 8wks (n=4-9/group). 
Quantitative mRNA analysis 





In situ hybridisation (ISH) 
Murine specific RNA probe (sense/anti-sense) generation and ISH protocols 
were as previously described[20]. Primer sequences for probe generation 
outlined in Suppl. Table 2. Mouse 6μm paraffin liver sections were used. 
Specific hybridisation conditions/probe concentrations were 42oC, 1.0μg/ml for 
Gli1; 45oC, 2.5μg/ml for Shh. Sense RNA probes on an adjacent section 
served as a negative control, returning no specific signal. 
Histology, immunohistochemistry and immunofluorescence 
Outlined Supplementary Material. Isotype IgG controls were conducted in 
parallel (Supp. Fig. 1). 
Cell culture/vector construction 
Outlined Supplementary Material. 
Viability assay 
Cells (7.5x105) were transfected with 40nM non-targeting control (NT2) or 
Smoothened siRNA (α-Smo; Dharmacon) using Lipofectamine2000 
(Invitrogen, USA) as per manufacturer’s instructions. After 6h, cells were 
harvested and seeded into 96-well plates at 4000 cells/well. Viability was 
assessed by fluorescence (FLUOstar Omega, Ortenberg, Germany) using 
ALAMAR blue reagent (Invitrogen) per manufacturers instruction. The same 





DNA (12μg) using Lipofectamine2000, after selection with blasticidin. 
Repeated minimum three times. 
Luciferase assays 
Cells (5x104/well) were seeded into 12-well plates and transfected in 
quadruplicate with 8xGli.pGL4.10[luc2] (0.9μg) and Renilla control pRL-TK 
(0.1μg; Promega, USA) using Lipofectamine2000. Cells were pre-treated for 
1h with inhibitors Erlotinib.HCl or SGX-523 (500nM; Selleck, USA) where 
appropriate, followed by 8h stimulation with murine recombinant SHH (1μg/ml; 
R&D Systems®, USA), EGF (20ng/mL; PeproTech Inc, USA) or HGF 
(20ng/mL; R&D Systems®) + inhibitors. For Smo knockdown/luciferase 
assays, cells (8x104/well) were co-transfected with NT2 or α-Smo siRNA with 
both reporter plasmids. Luc2 and Renilla luciferase activities were determined 
using the Dual-Luciferase® Reporter System (Promega). Repeated minimum 
three times. 
RESULTS 
1. Hedgehog ligand expression 
1.1 Intrahepatic ligand mRNA and protein expression 
The TAA model of chronic liver injury shows features of cirrhosis with 
increased classical injury markers, gene expression, activated hepatic stellate 
cells (HSCs) and LPCs within portal tracts by TAA-20wks (Supp. Fig. 2-4). An 
incremental increase in pan-Hh (SHH, IHH, DHH) N-terminal Hh signalling 





which cells upregulated Shh mRNA, ISH was performed. Shh+ve cells 
increased around central veins/portal tracts with treatment. By TAA-20wk 
there was a marked increase in Shh localised to the epithelial-mesenchymal 
interface, compared with minimal expression in control tissue (Fig. 1B). Large 
Shh+ve cells exhibited characteristics of dysmorphic hepatocytes, often 
isolated and within the portal tracts (Supp. Fig. 5A). In addition, small portal 
tract cells were Shh+ve, possibly implicating leukocytes, HSCs/myofibroblasts 
or LPCs as potential sources of Hh ligand. 
1.2 Hedgehog ligand protein detection in vivo 
To further characterise Hh-producing cells, immunohistochemistry was 
performed in liver tissue. Intense staining of IHH was localised to large 
damaged/dysmorphic hepatocytes in this chronic injury model (Fig. 1C). 
Confocal microscopy confirmed pan-Hh (SHH, IHH) protein expression within 
the fibrotic septa (Fig. 1D). The staining localised to large cells that co-
expressed epithelial cell marker pan-cytokeratin (pan-CK; Fig. 1E), providing 
confirmation hepatocytes were the primary source of Hh ligands. In contrast to 
the ISH data, no pan-Hh ligand protein was detected in small portal tract cell 
populations (Fig. 1F, Supp. Fig. 5B). However, Hh-producing hepatocytes 
were in close proximity to epithelial cell adhesion molecule (EpCAM)+ve LPCs, 
CD45+ve leukocytes and vimentin+ve activated HSCs (Fig. 1F, Supp. Fig 5B). 
The same expression profile was observed in human alcoholic liver disease 
(ALD), with CK18+ve hepatocytes at this interface the primary source of SHH 





2. Hedgehog pathway component expression 
2.1 Intrahepatic Hedgehog pathway expression 
The effectors of Hh pathway signalling are the GLI transcription factors, and 
since GLI proteins also regulate Gli1 transcription, this gene has been 
conventionally used as a readout of GLI activity. An incremental increase in 
whole liver Gli1 mRNA was observed from 4-20wks TAA (Fig. 2A). By TAA-
20wks this was accompanied by a significant increase in Ptc1 and Gli3, and a 
marked reduction in Hhip, a Hh pathway antagonist. Thus in TAA-induced 
cirrhosis, net upregulation of Hh signalling occurred with a combined 8.68-fold 
increase in Gli1 and 9-fold decrease in Hhip. Furthermore, increased GLI1-A 
and reduced GLI3-R (R, truncated/cleaved GLI3 repressor) proteins occurred 
by TAA-20wks (Fig. 2B). Protein levels of GLI target genes (OSTEOPONTIN, 
CYCLIN D1, BCL-2) were also increased. 
2.2 Gli1 mRNA localisation 
The cellular source(s) of GLI1 in chronic liver injury were yet to be 
determined. Since a reliable commercial anti-GLI1 antibody was not available, 
ISH was performed on TAA-20wk liver tissue to detect Gli1 mRNA. Gli1 
transcript was readily detectable in various cell populations at the epithelial-
mesenchymal interface (Fig. 2C). Notably, Gli1 was detected in large 
dysmorphic hepatocytes, as well as small portal tract cell populations, in TAA-
20wk liver. 





To determine which cell sub-population(s) could potentially respond to Hh 
signal, co-staining for cellular markers and GLI2 was performed. GLI2 was 
expressed by EpCAM+ve LPCs, as well as in a significant number of 
hepatocytes at the injury interface and lobule (Fig. 2D, Supp. Fig 7). 
Vimentin+ve HSCs/myofibroblasts and CD45+ve leukocytes were also GLI2+ve 
(Fig. 2E). Interestingly, co-expression of GLI2 and pan-Hh (SHH, IHH) ligand 
was observed in a subset of large cells with hepatocyte morphology (Suppl. 
Fig. 7B). This was consistent with our ISH data and suggests the large ligand-
producing cells exhibiting an active GLI response are injured hepatocytes, 
located at the epithelial-mesenchymal interface (Fig. 1,2C, Suppl. Fig 5A). 
2.4 Identification of ciliated cells in vivo 
In vertebrates, Hh ligands act on cells via SMO translocation to the Pc[8]. In 
TAA chronic liver injury, Pc were identified on numerous cells located within 
the portal tracts adjacent to the hepatic lobule (Fig. 3A). These cells 
expressed EpCAM (Fig. 3A, Suppl. Fig 8A) and SMO was localised within the 
Pc axoneme, a commonly used readout of SMO signalling (Fig. 3A). As 
identified earlier, EpCAM+ve cells also express GLI2 (Fig. 2D). Thus, these 
findings indicate the EpCAM+ve/Pc+ve/SMO+ve/GLI2+ve cell to be the 
compartment receiving Hh ligand signal in vivo. Further, ~32% of EpCAM+ 
cells were found to express Pc in vivo (Suppl. Fig 9A). However, this number 
most likely underrepresents the true number of Pc+/EpCAM+ cells due to loss 
of Pc through sectioning (with only one Pc per cell), and reabsorption of the 
Pc during cell-cycle re-entry. Moreover, although vimentin+ve, CD45+ve and 





(Suppl. Fig 8B, 9B and data not shown), suggesting these cell populations do 
not signal through Pc/SMO in vivo. These findings were corroborated in three 
independent laboratories on several occasions (McCaughan, Watkins, Tirnitz-
Parker). 
2.5 Characterisation of EpCAM+ve liver progenitor cells 
The Hh-responsive EpCAM+ve population, in close proximity to Hh-producing 
hepatocytes (Fig. 1F), was additionally always noted in close spatial 
association with fibrosis-driving α-smooth muscle actin (α-SMA)+ve HSCs 
(Suppl. Fig. 10A); a phenomenon commonly seen in chronic liver injuries with 
a LPC response[21]. Further, most EpCAM+ve cells co-expressed biliary LPC 
marker CK19, and LPC/cancer stem cell marker CD133 (Suppl. Fig. 10B,C). 
3. A Pc/SMO-dependent GLI-mediated response is important for liver 
progenitor cell survival in vitro 
To study the function of Hh signalling in Pc+ve liver cells in vitro, confocal 
microscopy was performed to determine which liver cell lines harbour Pc. 
BMOL1.2 LPCs were shown to have Pc (Suppl. Fig. 11A). Consistent with our 
in vivo observations, hepatocyte line H2.35 and HSC line LX-2 did not 
express Pc (Suppl. Fig 11B,C). SMO knockdown in Pc+ve LPC line BMOL1.2 
achieved between 70-90% reduction in nascent SMO (75 kDa), resulting in 
significantly (p<0.005) reduced cell proliferation by 48h treatment, and viability 
(Fig. 3B). Abrogation of SMO also reduced GLI-A, PTCH1, BCL-2 and 
CYCLIN D1 proteins, consistent with overall reduced cell viability. Further, 





(hGLI3R) exhibited significantly enhanced (p<0.0001) or reduced (p<0.0001) 
proliferation/viability (respectively) by day 6, as compared to controls (Fig. 
3C). This confirmed the importance of Hh pathway signalling in cell 
growth/expansion of Pc+ve LPCs. 
4. GLI-mediated transcriptional activity can be induced by growth 
factors in a SMO-independent manner in vitro 
Following our in vivo observations, we hypothesised that liver injury-related 
growth factors might induce SMO-independent GLI-mediated transcriptional 
responses in liver cells. To address this, we examined Hh pathway activation 
within the Pc+ve BMOL1.2 LPC line, using a Gli-luciferase reporter assay 
system. As predicted, BMOL1.2 cells treated with recombinant SHH (rSHH) 
significantly upregulated luciferase activity compared to controls (Fig. 3D). 
Injury factors epidermal growth factor (EGF) and HGF also significantly 
increased GLI-dependent transcription, and to the same degree as rSHH (Fig. 
3D). Upregulation of a GLI-mediated response by EGF/HGF was completely 
abolished using specific inhibitors (Erlotinib, SGX523) whilst having no effect 
on the basal GLI-mediated response (Fig. 3E). To assess the contribution of 
SMO-dependent and SMO-independent pathways in basal and induced GLI-
mediated transcriptional responses (luciferase activity), BMOL1.2 cells were 
treated with non-targeting control or α-Smo siRNAs (Fig. 3F). Intriguingly, α-
Smo inhibited EGF-dependent induction of GLI, but did not prevent HGF-
induced GLI signal. Also, although a significant decrease in basal luciferase 






5. Hh pathway manipulation in vivo: the functional role of SMO-
dependent Hh pathway activation in chronic liver injury 
Ptc1 heterozygous mice (Ptc1+/-) were used to test the contribution of SMO-
dependent Hh signalling in the TAA-induced liver injury model. Previous 
studies indicate Ptc1+/- mice have an impaired ability to regulate SMO-
dependent Hh pathway signal, thus have increased baseline Hh pathway 
activation[19, 22]. Following TAA-8wks, Ptc1+/- mice exhibited exacerbated 
liver injury compared to wt counterparts as determined by liver function testing 
and Picrosirius red staining for collagen I (Fig. 4A,D). Upregulated Gli1 
expression correlated with increased serum alanine aminotransferase (ALT) 
levels (Fig. 4B,C). Expansion of EpCAM+ve and vimentin+ve populations was 
evident when compared with wt controls, indicating amplified regenerative and 
fibrotic responses (Fig. 4D). Further, whole liver EpCAM and α-SMA protein 
levels were elevated in Ptc1+/- mice (Fig. 4E). Importantly, N-Hh protein 
increased with TAA-treatment, but levels were equivalent in wt and Ptc1+/- 
mice, although Ptc+/- mice exhibited increased Hh pathway activity (Fig. 4B,E). 
As Hh signalling has been implicated in epithelial-to-mesenchymal transition 
(EMT)[23], a selection of EMT genes were quantitated in wt vs. Ptc+/- TAA-
treated mice (Suppl. Fig 12A,B). The results show upregulation of EMT-
related genes (Vim, Bcl2, Snai1, Zeb2) in Ptc+/- mouse liver. However, the 
significant upregulation (p<0.01, Ptc+/- vs. wt TAA-treated) rather than 
downregulation of E-cadherin (Cdh1) does not support a specific EMT 





Gli1 expression with EMT-related Hh target genes (Bcl2, Snai1, Zeb2) (Suppl. 
Fig 12C). 
DISCUSSION 
The key observations in this paper define the intrahepatic niche of the Hh 
pathway in the TAA model of experimental cirrhosis. The major novel aspects 
of this paper are: (1) For the first time, Hh-responsive cells in the liver have 
been identified using Pc as a novel marker. (2) Characterisation of Hh 
signalling within the TAA injury model. (3) Use of ISH to detect cellular 
intrahepatic Shh/Gli1 mRNA in experimental chronic liver injury. The first 
finding is of particular importance given Pc are required to transduce the Hh 
ligand signal in vertebrates[8-10], and the emerging relevance of SMO-
independent GLI-mediated responses in injury and cancer[11-15]. 
Hh ligand production has previously been reported by injured biliary[22] and 
hepatocyte epithelium[24] in experimental models/human injury. Looking 
specifically at hepatocellular damage, we reported similar results with 
hepatocytes at the epithelial–mesenchymal border producing copious Hh 
ligand in human ALD (SHH) and following TAA (SHH, IHH). ISH indicated 
small cell populations also produced Shh. The mRNA/protein discrepancy is 
unexplained at present as no technical issues were identified. We can only 
conclude that in the TAA model Hh protein is produced by injured 
hepatocytes. Other studies have shown Hh ligands to be released by 
hepatocytes following ER stress[25] and apoptosis[24]. Further, in non-TAA 





endothelial cells[26], leukocytes[27] and LPCs[18] following primary culture or 
in vitro. 
Potential Hh-responsive cells have been identified in several models of liver 
injury and human liver diseases[16, 22, 23, 25, 28]. However, in these papers 
Hh-responsiveness in vivo has been defined by GLI2 staining only, without 
considering signalling via the Pc. Intrahepatic cell populations reported to be 
Hh-responsive include HSCs/myofibroblasts[17], endothelial cells[26], 
leukocytes[27] and LPCs[18]. Such a model proposes promiscuous Hh 
signalling to almost all cell populations within the liver during injury. We 
cannot refute the findings, as we noted Gli1 and GLI2 expression in similar 
populations. However Pc, the organelle required to transduce SMO-
dependent GLI transcriptional signals to downstream genes in vertebrate 
cells[8-10], were not detected in hepatocytes, leukocytes or myofibroblasts in 
vivo despite an intensive search. Previous studies have established that 
hepatocytes and leukocytes do not express a Pc[29]. A study of Pc 
expression by HSCs in human cirrhosis established 2.4% of HSCs (5 of 210 
cells) had an evident Pc[30]. The presence of SMO within the Pc, expressed 
by EpCAM+ve cells in vivo confirmed that these cells are competent at 
receiving and responding to Hh ligand signals[8]. 
Our findings confining Hh ligand cognate signalling to the 
EpCAM+ve/Pc+ve/SMO+ve/GLI+ve cell is compelling and is in keeping with Hh 
signal regulation that occurs in adult epithelial progenitor cell compartments in 





markers and further support the concept that Hh signalling is involved in 
maintaining the intrahepatic progenitor cell niche[18]. 
In light of our observations, previous studies that report widespread GLI-
mediated responses in multiple cell types without a Pc are likely to represent 
SMO-independent activation GLI via growth factors. Indeed, we demonstrated 
that EGF and HGF specifically induce a GLI-mediated transcriptional 
response. Interestingly, EGF/HGF induced a comparable response to rSHH in 
the LPC line BMOL1.2. To assess the contribution of SMO-dependent and 
SMO-independent GLI-mediated responses in BMOL1.2 cells in vitro, 
EGF/HGF treatment was coupled with α-Smo. HGF still induced GLI 
luciferase signal in SMO-depleted cells, suggesting that the GLI-mediated 
transcriptional response via HGF is SMO-independent. Emerging in vivo data 
supporting the concept of SMO-independent GLI-mediated responses was 
recently documented in kidney fibrosis[12] and pancreatic carcinogenesis[15]. 
Studies using BMOL1.2 cells suggested that growth factors can elicit a GLI-
mediated transcriptional response in Pc+ve cells in addition to the SMO-
dependent GLI-mediated response. As such, growth factors present during 
chronic liver injury may contribute to facilitation of a GLI-mediated 
transcriptional response in Pc+ve (e.g. LPCs) and Pc-ve (e.g. hepatocytes) cell 
compartments. Further, GLI activity was not abolished in unstimulated SMO-
depleted BMOL1.2 cells, indicating that SMO-independent processes of GLI 
activation may maintain basal GLI pathway signal. It is possible that multiple 





exist to exert a GLI-mediated signal in the LPC compartment, as maintenance 
of this signal is integral to cell survival within this population. 
Finally, we addressed whether genetic manipulation of the 
Hh/PTCH1/Pc/SMO cascade in vivo increased liver fibrosis in the TAA model. 
Prior studies have shown increased liver fibrosis in Ptc1+/- mice in other injury 
models[22, 23], and Ptc1+/- mice also exhibited increased fibrosis following 
hepatocellular TAA damage. Further, increased Hh activation, liver injury and 
amplified LPC and HSC/myofibroblast responses were observed. Importantly, 
expression of Hh ligands was not increased, confirming manipulation of the 
pathway itself rather than by a feedback loop.  
Thus, we confirmed with the current literature that in vivo manipulation of the 
Hh pathway alters the outcome of fibrosis[22, 23]. However, our interpretation 
using the TAA model and in vitro experimentation has led us to a paradigm 
distinct from the current literature (Fig. 4F). The literature proposes a chronic 
liver repair model whereby Hh ligands produced by multiple cell types drive 
SMO-dependent pathway activation in many cell types to promote 
inflammatory, regenerative and fibrogenic responses[16]. In particular, the 
pro-fibrogenic model suggests SMO-dependent signaling in the 
HSC/myofibroblast, which perpetuates the fibrotic response[17]. This model 
has recently been expanded to include SMO as a master regulator of many 
cell types including the transformation of HSC/myofibroblasts into liver 
progenitor cells and hepatocytes[31]. However, this paper did not use Pc as a 
marker for Hh-responsive cells, and studied alternate liver injury models (bile 





propose a more refined model of SMO-dependent pathway activation in TAA-
induced injury, where Hh ligands are produced locally by injured hepatocytes 
at the epithelial-mesenchymal interface. These cells are in close proximity to 
the LPC population, which receives paracrine Hh ligand signal via Pc. This 
drives subsequent expansion/growth of the LPC population. The close 
proximity of LPCs with HSCs/myofibroblasts implies cross talk between these 
populations. Other studies suggest LPCs may perpetuate HSC/myofibroblast 
activation/proliferation via cytokine/growth factor secretion[21]. We speculate 
GLI2+ve/Pc-ve populations (hepatocytes, leukocytes, myofibroblasts) also 
located within the Hh niche, are not responding to Hh ligand through SMO 
given they do not have a Pc and cannot transduce the Hh signal in vivo[8]. 
Instead, we suggest SMO-independent activation of GLI-mediated 
transcriptional response is occurring in these cell populations, driven by 
growth factors/cytokines and independent of Hh/PTCH1/Pc/SMO.  
There is no question the Hh signalling pathway plays an important role in 
chronic liver disease pathogenesis. Given the great potential for use of small 
molecule inhibitors of SMO in the treatment of liver disease, it is critical to 
dissect the contributions of both SMO-dependent and SMO-independent GLI-
mediated transcriptional responses in chronic liver disease. This has not been 
previously undertaken. The use of Pc as a marker to define Hh/PTCH1/SMO-
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Fig. 1. TAA-treatment induces Hh ligand mRNA/protein in hepatocytes located 
at the injury interface. (A) Western blot, pan-Hh N-terminal signalling peptide (N-
Hh, <25 kDa) in whole liver lysates and densitometry. Mean+S.E.M., One-way 
ANOVA, Dunnett’s multiple comparisons test; ***p<0.001 vs. control 20wk. (B) In situ 
hybridization detected Shh mRNA in TAA model. Brown/purple precipitate indicates 
Shh+ve cells. 10x objective. (C) Immunohistochemistry detected IHH protein (brown) 
in hepatocytes. 40x objective. (D) Immunofluorescence detected Hh ligand proteins 
(red) at the injury interface. 10x objective. (E) Hh ligands (red) within pan-cytokeratin 
(pan-CK)+ve hepatocytes. Confocal, 63x objective. (F) Hh-producing hepatocytes 
(red) adjacent to EpCAM+ve LPCs (green). 40x objective. (C-F) TAA-20wk liver. 
Fig. 2. Progressive activation of the Hh pathway occurs with TAA-treatment, 
and multiple liver cell populations express Gli1 and GLI2 in vivo. (A) qRT-PCR 
for Gli1, Ptc1, Gli3, Hhip transcripts in whole liver. Mean+S.E.M. Significant (*) 
difference between means. (B) Western blot; GLI1, GLI3-R, downstream Hh target 
(OSTEOPONTIN, CYCLIN D1, BCL-2) proteins in whole liver lysates. (C-E) TAA-
20wk liver. (C) In situ hybridisation for Gli1 mRNA. Purple precipitate indicates Gli1+ve 
small cells (solid arrows) and hepatocytes (dashed arrows) at injury interface. 10x 
(top), 40x (bottom) objective. Negative control, Gli1 sense (inset). (D) 
Immunofluorescence detected GLI2+ve nuclei (red) within EpCAM+ve LPCs (solid 
arrows). GLI2+ve hepatocyte nuclei (dashed arrow). 100x objective. (E) GLI2+ve nuclei 
(green) within vimentin+ve HSCs/myofibroblasts or CD45+ve leukocytes (red). 
Confocal, 63x objective. 
Fig. 3. Identification of primary cilia on Hh-responsive LPCs in vivo and the 
contribution of SMO-dependent/-independent GLI responses in vitro. (A) 





injury interface. Inset, fully assembled Pc: basal body (γ-tubulin, red) and axoneme 
(α-acetylated tubulin, green). Pc+ve cells expressed LPC marker EpCAM (white). 
SMO (green) localisation within ciliary axoneme (red). Confocal, 60x/100x objective. 
(B) SMO knockdown in Pc+ve BMOL1.2 LPC line. α-Smo reduced cell proliferation 
(fluorescence, Em 590nm) and viability vs. control (NT2, non-targeting). Concurrent 
decrease in Hh pathway/target proteins. (C) Proliferation (fluorescence)/viability 
following expression of V5-tagged GLI-A (hGLI1) and GLI-R (hGLI3R) vs. control 
(lacZ) in BMOL1.2s. Mean+S.E.M (n=6); Two-way ANOVA, multiple comparisons 
testing, α=0.001, ***p<0.005, #p<0.0001. Vector expression confirmed using anti-V5 
antibody by Western blot. (D-F) Co-transfection (8xGli-luciferase, Renilla luciferase 
constructs) assessed GLI luciferase activity in BMOL1.2 cells. (D) rSHH, EGF and 
HGF significantly upregulated GLI activity vs. untreated cells. (E) Pre-treatment with 
inhibitors (Erlotinib/SGX523) prior to EGF/HGF treatment abolished EGFR/c-MET 
induced GLI activity, respectively. (F) EGF/HGF treatment coupled with co-
transfection of α-Smo or NT2. (B, D-F) Mean+S.E.M. (n=4-6); Two-sided student t-
test; *p<0.05, **p<0.01, ***p<0.005, #p<0.0001.  
Fig. 4. Ptc+/- mice exhibit increased liver injury, Hh pathway activation, 
regenerative and fibrotic responses. (A) Serum alanine transaminase (ALT) and 
aspartate transaminase (AST) levels were increased in Ptc+/- vs. wt mice, following 
TAA. (B) qRT-PCR for Gli1 mRNA in whole liver. (C) Significant correlation of Gli1 
(Hh activation) with serum ALT levels (U/L; hepatocyte damage) (ALT vs. Gli1 
mRNA; Spearman r=0.6907; p=0.0011). (D) Representative Picrosirius red (PSR) 
stain, immunofluorescence for EpCAM (LPCs), vimentin (HSCs/myofibroblasts). 10x 
objective. (E) Western blot; EpCAM (39 kDa), α-SMA, N-Hh (<25 kDa) in whole liver 
lysates. (F) Proposed in vivo model. Mean+S.E.M., Mann-Whitney U test; *p<0.05, 
**p<0.01. 
  
  
  
  
